The U.S. Federal Trade Commission (FTC) filed an amended complaint Tuesday in federal court against Vyera Pharmaceuticals LLC (formerly Turing Pharmaceuticals AG) and its co-founders, Martin Shkreli and Kevin Mulleady, adding six new states as co-complainants. Originally filed in January, the complaint alleges an anticompetitive scheme by the defendants to preserve a monopoly for the antiparasitic Daraprim (pyrimethamine). When New York-based Turing acquired the drug in 2015, the drug had been an affordable, life-saving treatment for more than 60 years. Turing immediately raised the list price nearly 5,500% to $750 per tablet. To prevent generic competition, the defendants “crafted unlawful restrictive distribution agreements to keep competitors from buying the Daraprim samples they needed to conduct FDA-required tests,” according to the FTC. They also prevented competitors from accessing a critical ingredient needed to make the drug and signed “data blocking” agreements preventing several distributors from selling Daraprim sales data to third-party data reporting companies, the complaint alleges. The complaint also names Vyera’s parent company, Phoenixus AG, as a defendant. While Shkreli is serving prison time on a securities fraud conviction, Mulleady is currently serving as chairman of the board for the Baar, Switzerland-based Phoenixus.